4.7 Article

Correction of SMN2 pre-mRNA splicing by antisense U7 small nuclear RNAs

期刊

MOLECULAR THERAPY
卷 12, 期 6, 页码 1013-1022

出版社

CELL PRESS
DOI: 10.1016/j.ymthe.2005.08.022

关键词

spinal muscular atrophy; SMN1 gene product; SMN2 gene product; RNA splicing; alternative splicing; U7 snRNA; gene therapy

资金

  1. NIGMS NIH HHS [R01 GM062287, GM 07311, GM 62287] Funding Source: Medline

向作者/读者索取更多资源

Mutations in one of the duplicated survival of motor neuron (SMN) genes lead to the progressive loss of motor neurons and subsequent development of spinal muscular atrophy (SMA), a common, and usually fatal, hereditary disease. Homozygous absence of the telomeric copy (SMN1) correlates with development of SMA because differential splicing of the centromeric copy (SMN2) leads to exon 7 skipping and predominantly produces a biologically inactive protein isoform. To increase exon 7 inclusion of SMN2, we have designed a series of vectors that express modified U7 snRNAs containing antisense sequences complementary to the 3' splice site of SMN exon 8. Over 20 anti-SMN U7 snRNAs were tested for their ability to promote exon 7 inclusion in the SMN2 gene. Transient expression of anti-SMN U7 snRNAs in HeLa cells modulated SMN2 splicing to -70% exon 7 inclusion in a sequence-specific and dose-dependent manner. Significantly, the administration of anti-SMN U7 snRNPs results in an increase in the concentration of SMN protein. These results suggest that modulation of SMN2 pre-mRNA splicing by modified U7 snRNAs; provides a promising form of gene therapy for the treatment of SMA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据